AVTX vs NVS
AVTX: Clinical-stage biotech developing abdakibart, a humanized anti-IL-1β antibody for hidradenitis suppurativa with Phase 2 data readout expected mid-2026. NVS: Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases.
Side-by-side fundamentals
| Metric | AVTX | NVS | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $18.15 | $153.08 | |
| Market cap as of 2026-07-23 | $961M | $229.2B | |
| P/E as of 2026-07-23 | n/a | 22.11 | |
| PEG as of 2026-07-23 | n/a | 3.66 | |
| Net margin as of 2026-07-23 | -23254.2% | +22.5% | NVS higher |
| Gross margin as of 2026-07-23 | +242.2% | +75.0% | AVTX higher |
| Operating margin as of 2026-07-23 | -33461.0% | +29.9% | NVS higher |
| ROE as of 2026-07-23 | -77.8% | +29.9% | NVS higher |
| ROA as of 2026-07-23 | -61.7% | +11.1% | NVS higher |
| Debt / equity as of 2026-07-23 | 0.03 | 1.18 | AVTX lower |
| Revenue growth (YoY) as of 2026-07-23 | -86.6% | +3.3% | NVS higher |
| Revenue CAGR (3y) SEC XBRL | -85.2% | n/a | |
| Dividend yield as of 2026-07-23 | n/a | +3.0% | |
| Beta as of 2026-07-23 | 0.75 | 1.17 | |
| 1-year return as of 2026-07-22 close | +182.7% | +35.8% | AVTX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.